LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Lipid Profiles Investigated for Coronary Heart Disease Patients

By LabMedica International staff writers
Posted on 23 Nov 2016
Image: The Konelab 20XT clinical chemistry automated analyzer (Photo courtesy of Thermo Fisher Scientific).
Image: The Konelab 20XT clinical chemistry automated analyzer (Photo courtesy of Thermo Fisher Scientific).
Lipoprotein (a) (Lp (a)) excess is an independent risk factor of coronary artery disease (CAD) and has shown wide ethnic variations and lipid parameters used in the assessment and management of risk factors for CAD may not reflect accurately the disease or its severity.

Risk factors for Cardio Vascular Disease (CVD) comprise dyslipidemia, diabetes, hypertension, obesity, sedentary lifestyle, smoking, alcohol, family history, menopause and advancing age. Furthermore, homocysteine, fibrinogen, lipoprotein(a), low density lipoprotein particle size and C-reactive protein are the conditional risk factors that contribute to CVD.

Medical scientists at the University of Sri Jayewardenepura (Nugegoda, Sri Lanka) conducted a prospective cross sectional study during the years 2013 and 2014. The study sample consisted of 102 consenting patients awaiting Coronary Artery Bypass Graft (CABG) at the Cardiothoracic Unit of the local hospital. The majority of the patients (43.1 %) were between 51 and 60 years with 4.9 % less than 40 years. The mean age of male and female patients was 56.9 ± 10 and 57.8 ± 7.

Pre-operative blood samples were collected into plain tubes and the serum separated. Lp(a) content was measured by immunoturbidimetric method (Thermo Fisher Scientific, Helsinki, Finland) . The absorbance of the immune-complex, produced from Lp(a) and anti-serum was measured at 340 nm on a Thermo Scientific Konelab 20XT clinical chemistry automated analyzer. Data on total cholesterol, low density lipoprotein cholesterol (LDLc), high density lipoprotein cholesterol (HDLc), and triglyceride were collected from each patient’s data records and TC:HDLc ratio calculated.

The scientists reported that total cholesterol (TC), LDL cholesterol and HDL cholesterol of the total study sample (average ± SD) were, 150 ± 36 mg/dL, 92 ± 36 mg/dL and 34 ± 9 mg/dL respectively with no significant difference irrespective of being on pharmacological treatment or not. All lipid parameters were significantly high in females. The average Lp(a) was 50 ± 38 mg/dL with no significant difference in males or females independent of being on treatment (50 ± 39 mg/dL) or not (49 ± 39 mg/dL) and above the cut off value (30 mg/dL).

The authors concluded that despite pharmacological interventions 27 % of the study population had high LDLc and majority low HDLc. Mean Lp(a) was in excess irrespective of risk factors or being on treatment or not and is confirmed as an independent, potential marker for assessing the susceptibility for CAD especially in those with other intermediate risk factors but considered non-hyperlipidemic by conventional methods. The study was published on November 8, 2016, in the journal BMC Cardiovascular Disorders.

Related Links:
University of Sri Jayewardenepura
Thermo Fisher Scientific
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Alcohol Testing Device
Dräger Alcotest 7000

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more